Table 1.

Patients’ demographic, clinical and biochemical characteristics based on racial group.

	Hispanic (n=1,568)	Non-Hispanic White (n=2,242)	Non-Hispanic Black (n=1,714)	Non-Hispanic Asian (n=835)	p value
Age, years	45 ± 17	52 ± 20	48 ± 18	46 ± 16	<0.001
Gender, male/female %	48/52%	50/50%	47/53%	49/51%	0.41
Weight, kg	80 ± 19	84 ± 22	88 ± 24	69 ± 16	<0.001
Body mass index, kg/m2	30.0 ± 6.2	29.7 ± 7.2	31.1 ± 8.3	25.8 ± 4.8	<0.001
Presence of diabetes, %	20.9%	17.1%	20.7%	17.7%	0.004
A1c, %	5.9 ±1.3	5.7 ± 0.9	5.9 ± 1.2	5.8 ± 0.9	<0.001
Fasting plasma glucose, mg/dL	107 ± 43	102 ± 33	102 ± 36	101 ± 29	<0.001
Fasting plasma insulin, μU/mL	16 ± 17	15 ± 30	14 ± 17	12 ± 12	0.038
Total cholesterol, mg/dL	186 ± 39	185 ± 41	180 ± 39	192 ± 41	<0.001
LDL-C, mg/dL	111 ± 35	107 ± 35	107 ± 36	112 ± 35	0.012
HDL-C, mg/dL	50 ± 13	53 ± 15	55 ± 15	54 ± 16	<0.001
Triglycerides, mg/dL	152 ± 140	133 ± 92	96 ± 65	144 ± 116	<0.001
Statin use, %	16.1%	25.3%	18.3%	18.7%	<0.001
Presence of cardiometabolic risk factors (based on MASLD definition)
- High BMI or WC	86%	83%	81%	77%	<0.001
- High Glucose/A1c	54%	51%	57%	54%	0.003
- High BP	43%	52%	59%	43%	<0.001
- High triglycerides	27%	34%	23%	31%	<0.001
- Low HDL	51%	51%	43%	45%	<0.001
Aspartate aminotransferase (AST), U/L	22 ± 14	21 ± 11	20 ± 9	21 ± 9	<0.001
AST ≥ 30 among those with VCTE ≥ 9.7 kPa	31%	19%	7%	38%	<0.001
Alanine aminotransferase, U/L	25 ± 19	21 ± 16	19 ± 13	22 ± 15	<0.001
ALT ≥ 30 among those with VCTE ≥ 9.7 kPa	47%	33%	16%	46%	<0.001
CAP, dB/m	273 ± 62	266 ± 63	251 ± 61	258 ± 59	<0.001
Liver stiffness by VCTE, kPa	5.6 ± 4.0	5.9 ± 5.2	5.7 ± 3.8	5.0 ± 2.1	<0.001